Warning: The Last Value Play Gone After August?

From Oxford Club | Ad

In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward

Get the Details Now.

UTHR Insider Trading (United Therapeutics)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 12.10%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $25,901,446.03

United Therapeutics Insider Trading History Chart

United Therapeutics Share Price & Price History

^$185.38

▼ -5.61 (-2.94%)

As of 05/18/2022 05:00 PM ET

Days: 30 | 90 | 365

Invest in Artificial Intelligence Before It Changes the World

From HiveSkill | Ad

A.I. is going to be one of the dominant themes over the next decade, as companies automate their businesses and use A.I. to remain competitive. This is the golden age of investing in artificial intelligence!

Invest in this red-hot industry at pre-IPO prices.

United Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/5/2022	Paul A. Mahon	EVP	Sell	6,000	$190.65	$1,143,900.00	36,397
4/21/2022	Paul A. Mahon	EVP	Sell	6,000	$189.18	$1,135,080.00	36,397
4/7/2022	Paul A. Mahon	EVP	Sell	6,000	$185.52	$1,113,120.00	36,487
3/17/2022	Paul A. Mahon	EVP	Sell	6,000	$182.42	$1,094,520.00
3/3/2022	Paul A. Mahon	EVP	Sell	6,000	$174.12	$1,044,720.00
2/17/2022	Paul A. Mahon	EVP	Sell	6,000	$202.17	$1,213,020.00
2/3/2022	Paul A. Mahon	EVP	Sell	6,000	$200.10	$1,200,600.00
1/20/2022	Paul A. Mahon	EVP	Sell	6,000	$205.57	$1,233,420.00
1/6/2022	Paul A. Mahon	EVP	Sell	6,000	$192.46	$1,154,760.00
12/29/2021	Martine A Rothblatt	CEO	Sell	3,082	$212.49	$654,894.18
12/27/2021	Martine A Rothblatt	CEO	Sell	3,082	$213.31	$657,421.42
12/22/2021	Martine A Rothblatt	CEO	Sell	3,082	$202.44	$623,920.08
12/20/2021	Martine A Rothblatt	CEO	Sell	3,082	$200.00	$616,400.00
12/16/2021	Paul A. Mahon	EVP	Sell	6,000	$195.53	$1,173,180.00
12/2/2021	Paul A. Mahon	EVP	Sell	6,000	$189.36	$1,136,160.00
11/24/2021	Martine A Rothblatt	CEO	Sell	3,083	$200.64	$618,573.12
11/22/2021	Martine A Rothblatt	CEO	Sell	3,083	$200.42	$617,894.86
11/15/2021	Martine A Rothblatt	CEO	Sell	3,083	$203.45	$627,236.35
11/10/2021	Martine A Rothblatt	CEO	Sell	3,083	$200.00	$616,600.00
11/8/2021	Christopher Patusky	Director	Sell	2,300	$200.16	$460,368.00
11/8/2021	Martine A Rothblatt	CEO	Sell	3,083	$200.94	$619,498.02
11/4/2021	Martine A Rothblatt	CEO	Sell	3,083	$200.00	$616,600.00
11/4/2021	Paul A. Mahon	EVP	Sell	6,000	$201.19	$1,207,140.00
10/21/2021	Paul A. Mahon	EVP	Sell	6,000	$190.18	$1,141,080.00
10/7/2021	Paul A. Mahon	EVP	Sell	6,000	$190.52	$1,143,120.00
9/16/2021	Paul A. Mahon	EVP	Sell	6,000	$204.08	$1,224,480.00	42,369
9/2/2021	Paul A. Mahon	EVP	Sell	6,000	$210.94	$1,265,640.00	42,369
8/6/2021	Christopher Causey	Director	Sell	2,610	$210.00	$548,100.00
5/10/2021	Christopher Patusky	Director	Sell	100	$190.52	$19,052.00	4,800
4/1/2021	Judy D. Olian	Director	Sell	4,207	$184.96	$778,126.72	9,997
3/17/2021	Judy D. Olian	Director	Sell	2,103	$170.00	$357,510.00	7,893
7/8/2020	Martine A Rothblatt	CEO	Sell	10,000	$117.91	$1,179,100.00	10,140
7/6/2020	Martine A Rothblatt	CEO	Sell	10,000	$119.60	$1,196,000.00	10,140
7/2/2020	Martine A Rothblatt	CEO	Sell	10,000	$120.73	$1,207,300.00	10,140
6/30/2020	Martine A Rothblatt	CEO	Sell	10,000	$120.36	$1,203,600.00	10,140
6/29/2020	Raymond A. Dwek	Director	Sell	4,600	$116.81	$537,326.00	4,600
6/26/2020	Martine A Rothblatt	CEO	Sell	10,000	$121.00	$1,210,000.00	10,140
6/24/2020	Martine A Rothblatt	CEO	Sell	30,000	$119.54	$3,586,200.00	10,140
6/22/2020	Martine A Rothblatt	CEO	Sell	10,000	$117.81	$1,178,100.00	10,140
6/19/2020	Martine A Rothblatt	CEO	Sell	20,000	$116.35	$2,327,000.00	10,140
6/17/2020	Martine A Rothblatt	CEO	Sell	10,000	$117.82	$1,178,200.00	10,140
6/15/2020	Martine A Rothblatt	CEO	Sell	10,000	$113.87	$1,138,700.00	10,140
6/12/2020	Martine A Rothblatt	CEO	Sell	20,000	$115.42	$2,308,400.00	10,140
6/10/2020	Martine A Rothblatt	CEO	Sell	30,000	$122.86	$3,685,800.00	10,140
6/8/2020	Judy D. Olian	Director	Sell	4,510	$124.96	$563,569.60	3,490
6/5/2020	Martine A Rothblatt	CEO	Sell	10,000	$123.59	$1,235,900.00	10,140
6/3/2020	Martine A Rothblatt	CEO	Sell	10,000	$124.52	$1,245,200.00	10,140
6/1/2020	Martine A Rothblatt	CEO	Sell	10,000	$119.28	$1,192,800.00	10,140
5/29/2020	Martine A Rothblatt	CEO	Sell	10,000	$115.91	$1,159,100.00	10,140
5/27/2020	Martine A Rothblatt	CEO	Sell	10,000	$115.90	$1,159,000.00	10,140
5/5/2020	Tommy G Thompson	Director	Sell	3,100	$112.56	$348,936.00	9,050
4/20/2020	Richard Giltner	Director	Sell	5,000	$107.00	$535,000.00	8,750
4/14/2020	Richard Giltner	Director	Sell	5,000	$99.00	$495,000.00	8,750
3/26/2020	Richard Giltner	Director	Sell	5,000	$91.75	$458,750.00	8,750
6/27/2019	Raymond A. Dwek	Director	Sell	3,750	$76.11	$285,412.50	3,750
6/20/2019	Richard Giltner	Director	Sell	5,000	$79.05	$395,250.00	5,000

The Incredible Dividend Map... Where Stocks Yield 26% a Year!

From Investing Daily | Ad

What’s the highest-yielding stock you’ve ever owned?

The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.

Get in on the action here.

SEC Filings (Institutional Ownership Changes) for United Therapeutics (NASDAQ:UTHR)

94.68% of United Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

United Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/18/2022	BNP Paribas Arbitrage SA	16,171	$2.90M	0.0%	-55.2%	0.036%
5/17/2022	Walleye Capital LLC	22,341	$4.01M	0.1%	+1,012.0%	0.049%
5/17/2022	Weiss Multi Strategy Advisers LLC	14,610	$2.62M	0.1%	-21.2%	0.032%
5/17/2022	Roundview Capital LLC	2,881	$0.52M	0.1%	-20.3%	0.006%
5/17/2022	Penn Capital Management Company LLC	7,960	$1.43M	0.1%	-5.0%	0.018%
5/17/2022	Krensavage Asset Management LLC	201,612	$36.17M	12.5%	-1.6%	0.445%
5/17/2022	MidWestOne Financial Group Inc.	7,393	$1.33M	0.3%	N/A	0.016%
5/17/2022	Polar Asset Management Partners Inc.	60,100	$10.78M	0.1%	-4.6%	0.133%
5/17/2022	Polar Capital Holdings Plc	373,380	$66.99M	0.3%	-29.0%	0.824%
5/17/2022	Quantamental Technologies LLC	3,312	$0.59M	0.3%	N/A	0.007%
5/17/2022	Quinn Opportunity Partners LLC	11,403	$2.05M	0.1%	N/A	0.025%
5/17/2022	Royal Bank of Canada	23,234	$4.17M	0.0%	-36.0%	0.051%
5/17/2022	Dynamic Technology Lab Private Ltd	5,250	$0.94M	0.1%	N/A	0.012%
5/17/2022	Eaton Vance Management	19,053	$3.42M	0.0%	+2,948.5%	0.042%
5/17/2022	Ensign Peak Advisors Inc	65,182	$11.70M	0.0%	+11.4%	0.144%
5/17/2022	Eqis Capital Management Inc.	3,242	$0.58M	0.1%	+70.5%	0.007%
5/17/2022	Farallon Capital Management LLC	379,696	$68.12M	0.4%	+18.4%	0.838%
5/17/2022	First Manhattan Co.	83,600	$15M	0.0%	N/A	0.185%
5/17/2022	First Republic Investment Management Inc.	3,516	$0.63M	0.0%	+8.4%	0.008%
5/17/2022	Forum Financial Management LP	1,120	$0.20M	0.0%	+6.9%	0.002%
5/16/2022	California State Teachers Retirement System	57,531	$10.32M	0.0%	-7.8%	0.127%
5/16/2022	Goldman Sachs Group Inc.	173,328	$31.10M	0.0%	+2.5%	0.383%
5/16/2022	PDT Partners LLC	6,065	$1.09M	0.1%	N/A	0.013%
5/16/2022	Palo Alto Investors LP	653,079	$117.17M	9.1%	-5.0%	1.442%
5/16/2022	Captrust Financial Advisors	21,190	$3.80M	0.0%	-0.7%	0.047%
5/16/2022	Wellington Management Group LLP	1,675,414	$300.59M	0.1%	+73.7%	3.698%
5/16/2022	Brahman Capital Corp.	27,310	$4.90M	0.4%	-77.3%	0.060%
5/16/2022	State Street Corp	1,626,491	$291.81M	0.0%	+7.2%	3.590%
5/16/2022	Paradigm Biocapital Advisors LP	75,635	$13.57M	3.6%	N/A	0.167%
5/16/2022	Ethic Inc.	2,472	$0.44M	0.0%	N/A	0.005%
5/16/2022	Echo Street Capital Management LLC	5,149	$0.92M	0.0%	N/A	0.011%
5/16/2022	Eversept Partners LP	292,234	$52.43M	4.3%	-25.4%	0.645%
5/16/2022	Engineers Gate Manager LP	3,900	$0.70M	0.0%	N/A	0.009%
5/16/2022	Invesco Ltd.	232,531	$41.72M	0.0%	-18.3%	0.513%
5/16/2022	Clark Capital Management Group Inc.	12,478	$2.24M	0.0%	-32.8%	0.028%
5/16/2022	UBS Group AG	53,706	$9.64M	0.0%	-37.1%	0.119%
5/16/2022	Hsbc Holdings PLC	4,472	$0.80M	0.0%	-45.3%	0.010%
5/13/2022	Silverarc Capital Management LLC	14,836	$2.66M	1.1%	+2.0%	0.033%
5/13/2022	Wexford Capital LP	5,601	$1.01M	0.0%	-30.0%	0.012%
5/13/2022	Renaissance Technologies LLC	2,765,213	$496.11M	0.6%	-5.2%	6.104%
5/13/2022	Northern Trust Corp	342,295	$61.41M	0.0%	-3.2%	0.756%
5/13/2022	Cadence Bank	4,248	$0.76M	0.1%	-4.0%	0.009%
5/13/2022	Charles Schwab Investment Management Inc.	391,827	$70.30M	0.0%	+3.5%	0.865%
5/13/2022	Lazard Asset Management LLC	232,027	$41.63M	0.0%	-23.5%	0.512%
5/13/2022	Utah Retirement Systems	7,846	$1.41M	0.0%	-1.3%	0.017%
5/13/2022	Employees Retirement System of Texas	8,000	$1.44M	0.0%	N/A	0.018%
5/13/2022	Arrowstreet Capital Limited Partnership	4,893	$0.88M	0.0%	-96.3%	0.011%
5/13/2022	First Trust Advisors LP	417,503	$74.90M	0.1%	-19.0%	0.922%
5/13/2022	Prudential Financial Inc.	92,056	$16.52M	0.0%	+29.7%	0.203%
5/13/2022	Federated Hermes Inc.	13,603	$2.44M	0.0%	+0.5%	0.030%
5/13/2022	American International Group Inc.	76,286	$13.69M	0.1%	+0.2%	0.168%
5/13/2022	Fuller & Thaler Asset Management Inc.	664,295	$119.18M	0.7%	-9.2%	1.466%
5/13/2022	Parkman Healthcare Partners LLC	74,107	$13.30M	3.9%	-17.8%	0.164%
5/13/2022	Tekla Capital Management LLC	72,206	$12.95M	0.5%	-29.0%	0.159%
5/13/2022	Mackenzie Financial Corp	43,654	$7.83M	0.0%	+183.6%	0.096%
5/13/2022	Covestor Ltd	877	$0.16M	0.1%	+187.5%	0.002%
5/13/2022	Zions Bancorporation N.A.	368	$66K	0.0%	N/A	0.001%
5/13/2022	Loomis Sayles & Co. L P	69,653	$12.50M	0.0%	-5.5%	0.154%
5/13/2022	Vanguard Group Inc.	4,168,796	$747.93M	0.0%	+0.2%	9.203%
5/13/2022	Prudential PLC	6,467	$1.16M	0.0%	N/A	0.014%
5/13/2022	Allianz Asset Management GmbH	175,209	$31.43M	0.0%	-33.9%	0.387%
5/13/2022	Canada Pension Plan Investment Board	2,063	$0.37M	0.0%	+229.6%	0.005%
5/13/2022	Sei Investments Co.	59,693	$10.79M	0.0%	-3.8%	0.132%
5/13/2022	Atika Capital Management LLC	49,000	$8.79M	0.7%	N/A	0.108%
5/13/2022	Dimensional Fund Advisors LP	561,966	$100.81M	0.0%	-2.1%	1.241%
5/12/2022	LSV Asset Management	594,402	$106.64M	0.2%	+10.7%	1.312%
5/12/2022	Yousif Capital Management LLC	25,279	$4.54M	0.0%	+3.6%	0.056%
5/12/2022	Gyon Technologies Capital Management LP	3,045	$0.55M	0.4%	-41.9%	0.007%
5/12/2022	Great West Life Assurance Co. Can	28,326	$5.24M	0.0%	+8.9%	0.063%
5/12/2022	BlackRock Inc.	4,277,089	$767.35M	0.0%	+0.9%	9.442%
5/12/2022	Quent Capital LLC	8,171	$1.47M	0.3%	-3.8%	0.018%
5/12/2022	Commonwealth of Pennsylvania Public School Empls Retrmt SYS	16,506	$2.96M	0.0%	+10.5%	0.036%
5/12/2022	Rhumbline Advisers	114,867	$20.61M	0.0%	-3.2%	0.254%
5/12/2022	MetLife Investment Management LLC	29,109	$5.22M	0.0%	+33.4%	0.064%
5/12/2022	Martingale Asset Management L P	48,818	$8.76M	0.1%	+34.2%	0.108%
5/12/2022	Aureus Asset Management LLC	2,500	$0.45M	0.0%	N/A	0.006%
5/12/2022	Acadian Asset Management LLC	272,230	$48.82M	0.2%	-21.5%	0.601%
5/12/2022	OneAscent Wealth Management LLC	1,171	$0.21M	0.1%	N/A	0.003%
5/12/2022	Capital Fund Management S.A.	16,500	$2.96M	0.0%	N/A	0.036%
5/12/2022	Bank of Montreal Can	139,215	$24.45M	0.0%	+89.3%	0.307%
5/12/2022	E Fund Management Co. Ltd.	1,551	$0.28M	0.0%	N/A	0.003%
5/12/2022	AlphaCrest Capital Management LLC	5,683	$1.02M	0.1%	-28.9%	0.013%
5/12/2022	Eagle Health Investments LP	159,238	$28.57M	7.0%	+3.8%	0.352%
5/12/2022	King Wealth	9,500	$1.70M	0.3%	+26.7%	0.021%
5/12/2022	Citigroup Inc.	38,852	$6.97M	0.0%	-23.2%	0.086%
5/12/2022	Hancock Whitney Corp	12,234	$2.20M	0.1%	+263.7%	0.027%
5/12/2022	Mitsubishi UFJ Trust & Banking Corp	4,611	$0.83M	0.0%	-25.6%	0.010%
5/12/2022	Connor Clark & Lunn Investment Management Ltd.	52,802	$9.47M	0.0%	+34.4%	0.117%
5/12/2022	Oppenheimer Asset Management Inc.	35,548	$6.38M	0.1%	+7.4%	0.078%
5/12/2022	Oppenheimer & Co. Inc.	3,318	$0.60M	0.0%	-10.7%	0.007%
5/11/2022	Roundview Capital LLC	2,881	$0.52M	0.1%	-20.3%	0.006%
5/11/2022	American Century Companies Inc.	69,496	$12.47M	0.0%	+904.3%	0.153%
5/11/2022	Seven Eight Capital LP	1,998	$0.36M	0.0%	N/A	0.004%
5/11/2022	Bank of New York Mellon Corp	832,251	$149.32M	0.0%	-17.9%	1.837%
5/11/2022	Crossmark Global Holdings Inc.	5,148	$0.92M	0.0%	-8.9%	0.011%
5/11/2022	Polaris Capital Management LLC	354,200	$63.55M	2.0%	-5.5%	0.782%
5/11/2022	Massachusetts Financial Services Co. MA	15,808	$2.84M	0.0%	+1.4%	0.035%
5/11/2022	Raymond James & Associates	35,689	$6.40M	0.0%	-2.9%	0.079%
5/11/2022	Skandinaviska Enskilda Banken AB publ	700	$0.13M	0.0%	N/A	0.002%
5/11/2022	JPMorgan Chase & Co.	195,507	$35.08M	0.0%	-0.9%	0.432%

Data available starting January 2016

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Today's Range

Now: $185.38

$184.86

$192.20

50 Day Range

MA: $182.37

$167.78

$191.91

52 Week Range

Now: $185.38

$158.38

$218.38

Volume

370,330 shs

Average Volume

446,761 shs

Market Capitalization

$8.40 billion

P/E Ratio

12.83

Dividend Yield

N/A

Beta

0.64

Who are the company insiders with the largest holdings of United Therapeutics?: United Therapeutics' top insider shareholders include:
Paul A Mahon (EVP)
Martine A Rothblatt (CEO)
Judy D Olian (Director)
Christopher Patusky (Director)
Raymond Dwek (Director)
Christopher Causey (Director)
Learn More about top insider investors at United Therapeutics.
Who are the major institutional investors of United Therapeutics?: United Therapeutics' top institutional investors include:
BlackRock Inc. — 9.44%
Vanguard Group Inc. — 9.20%
Renaissance Technologies LLC — 6.10%
Wellington Management Group LLP — 3.70%
State Street Corp — 3.59%
Bank of New York Mellon Corp — 1.84%
Learn More about top institutional investors of United Therapeutics stock.
Which major investors are selling United Therapeutics stock?: In the last quarter, UTHR stock was sold by these institutional investors:
Robeco Institutional Asset Management B.V.
Bank of New York Mellon Corp
Polar Capital Holdings Plc
Renaissance Technologies LLC
Arrowstreet Capital Limited Partnership
Eversept Partners LP
First Trust Advisors LP
Brahman Capital Corp.
In the last year, company insiders that have sold United Therapeutics company stock include:
Paul A Mahon (EVP)
Martine A Rothblatt (CEO)
Judy D Olian (Director)
Christopher Patusky (Director)
Raymond Dwek (Director)
Learn More investors selling United Therapeutics stock.
Which major investors are buying United Therapeutics stock?: Within the last quarter, UTHR stock was purchased by institutional investors including:
Wellington Management Group LLP
Assenagon Asset Management S.A.
Twin Tree Management LP
Bank of Nova Scotia
State Street Corp
First Manhattan Co.
Paradigm Biocapital Advisors LP
Bank of Montreal Can